SPG-302 clinical trials
Also written SPG302.
How each study uses SPG-302 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SPG-302 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SPG302
- 6
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Spinogenix (6)
Studies
Open first, then newest update. How each study uses SPG-302 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Efficacy and Safety of Tazbentetol in ALS ParticipantsNot yet recruitingPhase 2/3SpinogenixNCT07325591Written as Tazbentetol
- Study of SPG302 in Adults With SchizophreniaActive, not recruitingPhase 2SpinogenixNCT06442462Written as SPG302
- Extension Study of Participants From SPG302-ALZ-101TerminatedPhase 2SpinogenixNCT06833281Written as SPG302
- Extension Study of Participants From SPG302-ALS-001TerminatedPhase 2SpinogenixNCT06903286Written as SPG302
- Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)Active, not recruitingPhase 2SpinogenixNCT06427668Written as SPG302
- Study of SPG302 in Healthy Volunteers and ALS ParticipantsCompletedPhase 1SpinogenixNCT05882695Written as SPG302